Pila Pharma AB Sustainability Reports
Pila Pharma AB is a clinical-stage biotech company developing oral small-molecule TRPV1 inhibitors. Its primary candidate, XEN-D0501, is designed as a novel treatment for obesity, type 2 diabetes, and related inflammatory or cardiovascular disorders.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 6488Z7WG18Q0ZN0V0262
FIGI: BBG00B6G5MM5
2 reports from 2021 to 2024
